1)- Hyunjung Kim, Tae Gyu Kim, Byungdo Park, Jeong Ho Kim, Si-Youl Jun, Jun Ho Lee, Hee Jun Choi, Chang Shin Jung, Yoon Ju Bang, Hyoun Wook Lee, Jae Seok Lee, Hyun Yeol Nam, Seunghyeon Shin, Sung Min Kim, Haeyoung Kim. Effect of high-dose radiation therapy on positive margins after breast-conserving surgery for invasive breast cancer.Breast (Edinburgh, Scotland). 2023, 71: 106-112
2)- Alberto Zambelli, Marina Cazzaniga, Nicla La Verde, Elisabetta Munzone, Ippazio Cosimo Antonazzo, Lorenzo Giovanni Mantovani, Serena Di Cosimo, Anna Mancuso, Daniele Generali, Paolo Angelo Cortesi. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy.Breast (Edinburgh, Scotland). 2023, 71: 113-121
3)- Kathy Dempsey, Erin Mathieu, Meagan Brennan, Kylie Snook, Julia Hoffman, Ian Campbell, Jenni Scarlet, Heather Flay, April Wong, Frances Boyle, Madeleine King, Andrew Spillane. Patient-reported health-related quality of life outcomes following mastectomy for breast cancer, with immediate, delayed or no breast reconstruction: Four-year follow-up from a prospective cohort study.Breast (Edinburgh, Scotland). 2023, 71: 122-131
5)- Serena Di Cosimo, Silva Ljevar, Annalisa Trama, Alice Bernasconi, Paolo Lasalvia, Maria Carmen De Santis, Vera Cappelletti, Rosalba Miceli, Giovanni Apolone. Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients.Breast (Edinburgh, Scotland). 2023, 71: 60-62
6)- Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.Breast (Edinburgh, Scotland). 2023, 71: 63-68
7)- Wei Chen, Fen-Xiang Li, Da-Lin Lu, Jun Jiang, Junjie Li. Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy.Breast (Edinburgh, Scotland). 2023, 71: 69-73
8)- Keris Poelhekken, Yixuan Lin, Marcel J W Greuter, Bert van der Vegt, Monique Dorrius, Geertruida H de Bock. The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review.Breast (Edinburgh, Scotland). 2023, 71: 74-81
9)- A Agrawal, L Romics, D Thekkinkattil, M Soliman, M Kaushik, P Barmpounakis, C Mortimer, C A Courtney, A Goyal, E Garreffa, A Carmichael, R A Lane, C Rutherford, B Kim, R Achuthan, V Pitsinis, S Goh, B Ray, K Grover, R Vidya, J Murphy, . 'PartBreCon' study. A UK multicentre retrospective cohort study to assess outcomes following PARTial BREast reCONstruction with chest wall perforator flaps.Breast (Edinburgh, Scotland). 2023, 71: 82-88
10)- Annemiek K E van Hemert, Frederieke H van Duijnhoven, Marie-Jeanne T F D Vrancken Peeters. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.Breast (Edinburgh, Scotland). 2023, 71: 89-95
11)- Marco Driutti, Luigino Dal Maso, Federica Toffolutti, Giulia Valdi, Ettore Bidoli, Fabiola Giudici, Maria Parpinel, Diego Serraino. Breast cancer deaths attributable to alcohol consumption: Italy, 2015-2019.Breast (Edinburgh, Scotland). 2023, 71: 96-98
12)- S Emily Bachert, Virgilius Cornea, Thérèse Bocklage. Adenosquamous proliferation in radial sclerosing lesions: Histologic spectrum and key features in systematic review of 247 lesions.Breast (Edinburgh, Scotland). 2023, 71: 99-105